A few STING agonists, MK-1454 (Merck) and MIW815 (Norvatis), are currently undergoing phase I clinical trials in combination with anti-PD1 immune checkpoint inhibitors in advanced/metastatic solid tumors and lymphomas (NCT03172936, NCT03172936), respectively 30, 31. The gene discussed is STING1; the disease is lymphoma.